Desmoplastic small round cell tumor (DSRCT) is a rare and highly malignant soft tissue sarcoma. Most patients are diagnosed at advanced stage unless DSRCT happens to be discovered accidentally. DSRCT mainly occurs in the abdomen and pelvis, spreading along the peritoneal surface. At the time of diagnosis, most patients have passed the operable stage. The diagnosis of DSRCT is based on the histological analysis of a biopsy. It typically manifests as small round blue cells in the nest, separated by a large number of fibroproliferative stroma. A stable cytogenetic feature of DSRCT is that the characteristic t(11; 22) (P13; Q12) chromosome produces the EWSWT1 fusion gene. The prognosis of patients with DSRCT is very poor, and the 5-year survival rate is about 15%. Despite the use of active treatment methods, such as chemotherapy, surgery, and total abdominal radiotherapy, about 60% 70% of patients with DSRCT die within 2- 3 years. Targeted therapy, immunotherapy, and other methods have been trialed recently in the treatment of DSRCT due to the development of DSRCT molecular genetics.

Objective To conduct a visual analysis of the current status,hotspots,and frontiers of research on renal cell carcinoma targeted therapy using VOSviewer software.Methods Literature related to renal cell carcinoma targeted therapy published between January 1,2006 and December 31,2023,from the Web of Science(WOS)Core Collection database were retrieved.Eligible articles were screened and subjected to bibliometric and visual analysis using VOSviewer software.Results A total of 1,009 articles were selected,with an overall increasing trend in annual publication volume.The top three countries in terms of publication output were the United States,China,and Italy,while the top three institutions were Harvard University,The University of Texas,and France Uni-cancer Insti-tute.The analysis of the core author collaboration network revealed close collaboration among re-searchers in the United States and the United Kingdom,whereas collaboration between China and for-eign countries was limited,resulting in a relatively loose collaboration network.Through co-occur-rence clustering analysis of high-frequency author keywords,nine clusters were generated,with hotspots focusing on targeted and immune combination therapy,efficacy,prognosis,drug resistance,targets,and biomarkers.Conclusion Remarkable progress has been made in renal cell carcinoma tar-geted therapy research over the past decade;however,drug resistance and adverse reactions to targeted therapies remain challenges in clinical treatment.Research related to targeted drug resistance mechanisms,novel targeted drugs,and effective predictive biomarkers has significantly increased.Grasping the developmental trends in this fieldis crucial,and VOSviewer's visual analysis can offer an intuitive representation of the current status,hotspots,and frontiers,thereby providing research-ers with a valuable reference.

Objective To conduct a visual analysis of the current status,hotspots,and frontiers of research on renal cell carcinoma targeted therapy using VOSviewer software.Methods Literature related to renal cell carcinoma targeted therapy published between January 1,2006 and December 31,2023,from the Web of Science(WOS)Core Collection database were retrieved.Eligible articles were screened and subjected to bibliometric and visual analysis using VOSviewer software.Results A total of 1,009 articles were selected,with an overall increasing trend in annual publication volume.The top three countries in terms of publication output were the United States,China,and Italy,while the top three institutions were Harvard University,The University of Texas,and France Uni-cancer Insti-tute.The analysis of the core author collaboration network revealed close collaboration among re-searchers in the United States and the United Kingdom,whereas collaboration between China and for-eign countries was limited,resulting in a relatively loose collaboration network.Through co-occur-rence clustering analysis of high-frequency author keywords,nine clusters were generated,with hotspots focusing on targeted and immune combination therapy,efficacy,prognosis,drug resistance,targets,and biomarkers.Conclusion Remarkable progress has been made in renal cell carcinoma tar-geted therapy research over the past decade;however,drug resistance and adverse reactions to targeted therapies remain challenges in clinical treatment.Research related to targeted drug resistance mechanisms,novel targeted drugs,and effective predictive biomarkers has significantly increased.Grasping the developmental trends in this fieldis crucial,and VOSviewer's visual analysis can offer an intuitive representation of the current status,hotspots,and frontiers,thereby providing research-ers with a valuable reference.